Quarterly ResultAug 4, 2026, 07:10 AM
Rhythm Q2 Revenue $71.3M; IMCIVREE HO Launch Strong with 400+ Forms
AI Summary
Rhythm Pharmaceuticals reported Q2 2026 net product revenue of $71.3 million, driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), which saw over 400 patient start forms. The company also announced positive Phase 2 results for setmelanotide in Prader-Willi syndrome and preliminary data for RM-718 in acquired HO. Rhythm maintains a strong cash position of $330.9 million and expects its cash to fund operations for at least 24 months.
Key Highlights
- Global IMCIVREE net product revenue reached $71.3 million in Q2 2026.
- U.S. IMCIVREE revenue was $51.0 million, up 38% sequentially from Q1 2026.
- Over 400 patient start forms for IMCIVREE in acquired HO received since FDA approval.
- RM-718 achieved mean BMI reduction of 11.6% in 7 acquired HO patients.
- Cash, cash equivalents, and short-term investments totaled $330.9 million.
- Q2 2026 R&D expenses were $43.4 million, and SG&A expenses were $67.4 million.
- Net loss attributable to common stockholders was $(50.4) million for Q2 2026.
- Anticipates Non-GAAP Operating Expenses of $363M to $397M for full-year 2026.
Price Impact
More from RYTM